Candel Therapeutics Income Statement (2020-2025) | CADL

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Shares Outstanding (Entity) (Quarter)
11.65M11.73M23.33M18.87M28.69M29.01M29.01M29.04M29.04M29.04M29.04M29.21M29.47M31.19M32.25M31.68M49.37M55.01M55.02M55.02M
Revenue & cost
Revenue (Quarter)
0.03M0.03M0.03M0.01M0.03M0.03M0.03M0.03M
Operating items
Research & Development (Quarter)
2.75M3.29M5.26M3.85M5.42M5.02M5.38M4.97M5.47M5.93M5.84M7.26M0.83M4.98M2.20M-3.45M1.25M6.99M8.46M0.29M
Wages, Salaries and Other (Quarter)
1.67M1.21M1.68M1.65M1.93M1.95M1.21M2.02M
Selling, General & Administrative (Quarter)
1.94M2.04M2.79M3.92M3.60M3.76M3.54M3.16M4.16M3.65M3.02M3.06M3.80M3.59M3.34M3.32M4.11M4.19M4.75M4.72M
Restructuring Costs (Quarter)
0.49M0.52M0.46M0.49M0.46M0.46M0.44M0.48M
Other Operating Expenses (Quarter)
2.78M-0.52M2.75M7.78M2.31M-0.46M-0.44M10.26M
Operating Expenses (Quarter)
4.69M5.33M8.06M7.77M9.02M8.78M8.91M8.13M9.63M9.58M8.86M10.32M7.90M8.57M8.76M8.14M8.13M11.18M13.21M15.75M
Operating Income (Quarter)
-4.66M-5.30M-8.03M-7.74M-8.99M-8.75M-8.88M-8.10M-9.63M-9.58M-8.86M-10.32M-7.90M-8.57M-8.76M-8.14M-8.13M-11.18M-13.21M-15.75M
EBIT (Quarter)
-4.66M-5.30M-8.03M-7.74M-8.99M-8.75M-8.88M-8.10M-9.63M-9.58M-8.86M-10.32M-7.90M-8.57M-8.76M-8.14M-8.13M-11.18M-13.21M-15.75M
Non-operating items
Interest & Investment Income (Quarter)
-0.01M-0.01M0.13M0.15M0.07M0.34M-0.37M0.01M0.01M0.01M0.41M0.32M0.24M0.24M0.29M0.93M0.93M0.95M1.10M
Non Operating Income (Quarter)
0.18M-11.78M-8.13M9.34M8.11M4.60M0.19M3.02M0.84M-0.04M0.43M-0.78M-0.32M-13.67M-1.89M-5.93M15.51M6.38M1.94M-13.74M
Net income details
EBT (Quarter)
-4.67M-5.32M-7.90M-26.08M-38.15M-9.12M-9.06M-8.52M-10.23M-19.57M-9.52M-10.46M-8.23M-25.72M-28.82M-7.95M-21.05M-21.52M-23.65M-15.23M
Profit After Tax (Quarter)
-4.48M-17.08M-16.16M1.60M-0.87M-4.15M-8.69M-5.09M-8.80M-9.61M-8.44M-11.10M-8.20M-22.24M-10.65M-14.07M7.38M-4.80M-11.27M-29.50M
Income from Continuing Operations (Quarter)
-4.67M-5.32M-7.90M-26.08M-38.15M-9.12M-9.06M-8.52M-10.23M-19.57M-9.52M-10.46M-8.23M-25.72M-28.82M-7.95M-21.05M-21.52M-23.65M-15.23M
Consolidated Net Income (Quarter)
-4.67M-5.32M-7.90M-26.08M-38.15M-9.12M-9.06M-8.52M-10.23M-19.57M-9.52M-10.46M-8.23M-25.72M-28.82M-7.95M-21.05M-21.52M-23.65M-15.23M
Income towards Parent Company (Quarter)
-4.67M-5.32M-7.90M-26.08M-38.15M-9.12M-9.06M-8.52M-10.23M-19.57M-9.52M-10.46M-8.23M-25.72M-28.82M-7.95M-21.05M-21.52M-23.65M-15.23M
Net Income towards Common Stockholders (Quarter)
-4.67M-5.32M-7.90M-26.08M-38.15M-9.12M-9.06M-8.52M-10.23M-19.57M-9.52M-10.46M-8.23M-25.72M-28.82M-7.95M-21.05M-21.52M-23.65M-15.23M
Additional items
EPS (Basic) (Quarter)
-0.40-0.45-0.34-1.38-1.33-0.32-0.31-0.30-0.35-0.68-0.33-0.36-0.28-0.86-0.90-0.25-0.42-0.42-0.43-0.29
EPS (Diluted) (Quarter)
-0.45-0.34-1.38-1.33-0.32-0.31-0.30-0.35-0.68-0.33-0.36-0.28-0.86-0.90-0.25-0.38-0.42-0.43-0.29
Shares Outstanding (Quarter)
11.65M11.72M23.33M18.87M28.69M28.81M28.89M28.82M28.92M28.92M28.92M28.94M29.20M29.88M32.01M31.68M50.48M51.49M54.89M52.96M
Shares Outstanding (Diluted) (Quarter)
11.72M23.33M18.87M28.69M28.81M28.89M28.82M28.92M28.92M28.92M28.94M29.20M29.88M32.01M31.68M54.77M51.49M54.89M52.96M
EBITDA (Quarter)
-4.66M-5.30M-8.03M-7.74M-8.99M-8.75M-8.88M-8.10M-9.63M-9.58M-8.86M-10.32M-7.90M-8.57M-8.76M-8.14M-8.13M-11.18M-13.21M-15.75M
Interest Expenses (Quarter)
18.49M29.17M0.43M0.52M0.05M0.61M10.00M0.67M0.56M0.65M17.39M20.30M0.10M13.85M11.27M11.39M0.58M